Clinical Trial Update: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of tipifarnib and alpelisib in adults with recurrent or metastatic head and neck squamous cell carcinoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Alpelisib (alpelisib)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: HNSCC | Phase 1, Phase 2 | Status: COMPLETED